Healthcare DIVE October 1, 2024
Threatened with steep sanctions and losing access to Medicare and Medicaid, Johnson and Johnson is rolling back a plan to give hospitals after-the-fact rebates for 340B drugs.
Dive Brief:
- Johnson & Johnson has dropped a controversial plan to change how it discounts select drugs for hospitals, following extensive pushback from providers and the federal government.
- J&J wanted to pay hospitals after-the-fact rebates for two widely prescribed medications in the 340B Drug Discount Program, instead of discounting prices at the point of sale. Less than one month ago, the Health Resources and Services Administration sent J&J a letter threatening sanctions if the drugmaker enacted the program, noting it hadn’t received federal approval.
- On Monday, J&J notified HRSA that it would...
Today's Sponsors
Today's Sponsor